Publication Name	World Journal of Clinical Oncology
Manuscript ID	62012
Country	Spain

Received	2020-12-25 21:37
Peer-Review Started	2020-12-25 21:38
To Make the First Decision
Return for Revision	2021-09-29 10:28
Revised	2021-10-05 19:35
Second Decision	2022-01-10 05:44
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2022-01-10 22:58
Articles in Press	2022-01-10 22:58
Publication Fee Transferred
Edit the Manuscript by Language Editor	2022-01-05 11:08
Typeset the Manuscript	2022-01-17 13:15
Publish the Manuscript Online	2022-01-22 06:17

ISSN	2218-4333 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Editorial
Article Title	Update on the treatment of metastatic renal cell carcinoma
Manuscript Source	Invited Manuscript
All Author List	Rafael Antonio Medina López, Ines Rivero Belenchon, Javier Mazuecos-Quirós, Carmen Belén Congregado-Ruíz and Felipe Couñago
ORCID	Author(s) ORCID Number Rafael Antonio Medina López http://orcid.org/0000-0002-4514-4329 Ines Rivero Belenchon http://orcid.org/000-0002-6217-4618 Javier Mazuecos-Quirós http://orcid.org/0000-0001-5338-7526 Carmen Belén Congregado-Ruíz http://orcid.org/0000-0001-8801-0614 Felipe Couñago http://orcid.org/0000-0001-7233-0234
Funding Agency and Grant Number
Corresponding Author	Ines Rivero Belenchon, MD, Staff Physician, Department of Urology and Nephrology, Virgen del Rocío University Hospital, Manuel Siurot s/n, Seville 41005, Spain. ines.rivero.belenchon@gmail.com
Key Words	Metastatic renal cell carcinoma; Systemic treatment; Immune checkpoint inhibitors; Antiangiogenic; Update; Biomarkers
Core Tip	Kidney cancer therapeutics is a fast-changing field, and the outcome of metastatic renal cell carcinoma (mRCC) has thus improved considerably in recent years with the introduction of different combinations of immune checkpoint and vascular endothelial growth factors inhibitors. State-of-the-art systemic therapy regimens must be addressed to be in a position to offer patients the best options. The aim of this editorial is to provide an update and insight on future directions on mRCC management.
Publish Date	2022-01-22 06:17
Citation	Medina López RA, Rivero Belenchon I, Mazuecos-Quirós J, Congregado-Ruíz CB, Couñago F. Update on the treatment of metastatic renal cell carcinoma. World J Clin Oncol 2022; 13(1): 1-8
URL	https://www.wjgnet.com/2218-4333/full/v13/i1/1.htm
DOI	https://dx.doi.org/10.5306/wjco.v13.i1.1

Full Article (PDF)	WJCO-13-1.pdf
Full Article (Word)	WJCO-13-1.docx
Manuscript File	62012_Auto_Edited-JJW-WangTQ.docx
Answering Reviewers	62012-Answering reviewers.pdf
Audio Core Tip	62012-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	62012-Conflict-of-interest statement.pdf
Copyright License Agreement	62012-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	62012-Language certificate.pdf
Peer-review Report	62012-Peer-review(s).pdf
Scientific Misconduct Check	62012-Bing-Wang JJ-2.png
Scientific Editor Work List	62012-Scientific editor work list.pdf
CrossCheck Report	62012-CrossCheck report.pdf